Generic Olux E Foam® Launches

Released: 02/04/2013   By: Mike Partridge, RPh

On February 1, 2013, Perrigo received final FDA approval for and commenced shipping the generic equivalent for Stiefel Laboratories’ branded product, Olux E Foam® (clobetasol propionate). Olux E Foam® had estimated total U.S. annual sales of approximately $40 million.
Olux E Foam® is a corticosteroid indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.